Hansoh Pharmaceutical

Hansoh Pharmaceutical, a Chinese Pharmaceutical Preparation Manufacturing company, reported its total greenhouse gas emissions for 2025 as approximately 223,077,930 kg CO2e. This includes about 11,833,890 kg CO2e from Scope 1, 97,828,710 kg CO2e from Scope 2, and 93,115,140 kg CO2e from Scope 3.

For 2024, Hansoh Pharmaceutical's total emissions were approximately 157,115,000 kg CO2e, comprising around 13,163,250 kg CO2e from Scope 1, 88,227,050 kg CO2e from Scope 2, and 55,724,800 kg CO2e from Scope 3. In 2023, the company reported Scope 1 emissions of approximately 10,546,850 kg CO2e and Scope 2 emissions of about 81,565,210 kg CO2e.

Looking back to 2022, Hansoh Pharmaceutical's emissions included approximately 9,024,600 kg CO2e from Scope 1 and 77,719,970 kg CO2e from Scope 2. Specific Scope 3 categories were also reported for 2022: capital goods at approximately 28,230 kg CO2e, purchased goods and services at about 1,445,300 kg CO2e, and upstream transportation and distribution at around 94,070 kg CO2e.

In 2021, the company's Scope 1 emissions were approximately 6,256,000 kg CO2e, and Scope 2 emissions were about 116,072,000 kg CO2e. For 2020, Hansoh Pharmaceutical reported total emissions of approximately 104,650,000 kg CO2e, with Scope 1 at about 4,423,480 kg CO2e and Scope 2 at around 100,226,420 kg CO2e.

Hansoh Pharmaceutical has set climate commitments to reduce its environmental impact. By 2030, the company aims to decrease greenhouse gas emissions per unit of revenue from Scope 1 and Scope 2 by 40%, using 2021 as the baseline year. Additionally, Hansoh Pharmaceutical intends to reduce comprehensive energy consumption per unit of revenue by 20% by 2030, also with 2021 as the base year. The emissions and reduction targets data are cascaded from Hansoh Pharmaceutical Group Company Limited.